Literature DB >> 1248000

Malignant neoplasms in the families of patients with ataxia-telangiectasia.

M Swift, L Sholman, M Perry, C Chase.   

Abstract

Ataxia-telangiectasia (A-T) is an autosomal recessive syndrome associated with a greatly increased incidence of malignant neoplasms in homozygous affected individuals. Heterozygotes for the gene for A-T are thought to comprise about 1% of the general population and, therefore, it is important to know whether this gene also predisposes the heterozygous carrier to cancers. Heterozygous carriers of this gene are common among the close relatives of patients with A-T, although individual carriers cannot be identified by any clinical criterion or laboratory test. For this reason, we compared the incidence of death from malignant neoplasms in 2 families of patients with A-T to that expected in a random sample of the general population. There were 59 deaths from malignant neoplasms in relatives dying before age 75, compared to 42.6 expected (p less than 0.02). For A-T heterozygotes younger than age 45, the risk of dying from a malignant neoplasm was estimated to be greater than 5 times the risk for the general population. A-T heterozygotes may comprise more than 5% of all persons dying from a cancer before age 45. The incidence of ovarian, gastric, and biliary system carcinomas and of leukemia and lymphoma was increased in these A-T families. Other neoplasms that may be associated with this gene in heterozygotes include pancreatic, basal cell, colonic, breast, and cervical carcinomas.

Entities:  

Mesh:

Year:  1976        PMID: 1248000

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  55 in total

Review 1.  Genetic and biochemical studies with ataxia telangiectasia. A review.

Authors:  P C Huang; R B Sheridan
Journal:  Hum Genet       Date:  1981       Impact factor: 4.132

2.  Selective defects in T cell function in ataxia-telangiectasia.

Authors:  W R Levis; A M Dattner; J S Shaw
Journal:  Clin Exp Immunol       Date:  1979-07       Impact factor: 4.330

3.  Heterogeneity in the clastogenic response to X-rays in lymphocytes from ataxia-telangiectasia heterozygotes and controls.

Authors:  J K Wiencke; D W Wara; J B Little; K T Kelsey
Journal:  Cancer Causes Control       Date:  1992-05       Impact factor: 2.506

4.  Ataxia-telangiectasia: mutations in ATM cDNA detected by protein-truncation screening.

Authors:  M Telatar; Z Wang; N Udar; T Liang; E Bernatowska-Matuszkiewicz; M Lavin; Y Shiloh; P Concannon; R A Good; R A Gatti
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

5.  Autoimmunity in the relatives of patients with immunodeficiency diseases.

Authors:  J M Friedman; P J Fialkow; S D Davis; H D Ochs; R J Wedgwood
Journal:  Clin Exp Immunol       Date:  1977-06       Impact factor: 4.330

Review 6.  Defining molecular and cellular responses after low and high linear energy transfer radiations to develop biomarkers of carcinogenic risk or therapeutic outcome.

Authors:  Michael Story; Liang-hao Ding; William A Brock; K Kian Ang; Ghazi Alsbeih; John Minna; Seongmi Park; Amit Das
Journal:  Health Phys       Date:  2012-11       Impact factor: 1.316

7.  Cranial MRI in ataxia-telangiectasia.

Authors:  F Sardanelli; R C Parodi; C Ottonello; P Renzetti; S Saitta; E Lignana; G L Mancardi
Journal:  Neuroradiology       Date:  1995-01       Impact factor: 2.804

8.  Gastric adenocarcinoma due to ataxia-telangiectasia (Louis-Bar syndrome).

Authors:  M A Frais
Journal:  J Med Genet       Date:  1979-04       Impact factor: 6.318

9.  Gene expression phenotype in heterozygous carriers of ataxia telangiectasia.

Authors:  Jason A Watts; Michael Morley; Joshua T Burdick; Jennifer L Fiori; Warren J Ewens; Richard S Spielman; Vivian G Cheung
Journal:  Am J Hum Genet       Date:  2002-09-11       Impact factor: 11.025

10.  The incidence and gene frequency of ataxia-telangiectasia in the United States.

Authors:  M Swift; D Morrell; E Cromartie; A R Chamberlin; M H Skolnick; D T Bishop
Journal:  Am J Hum Genet       Date:  1986-11       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.